Evidence check: VKORC1 in the context of menopause

VKORC1 encodes subunit 1 of the vitamin K epoxide reductase complex, a key enzyme for vitamin K recycling. Vitamin K is essential for activating clotting factors as well as matrix Gla protein (MGP) and osteocalcin – both relevant for vascular calcification and bone metabolism. During menopause, estrogen decline increases risks for osteoporosis and cardiovascular disease. Polymorphisms in VKORC1 (e.g., rs9923231) affect vitamin K cycling and thus may indirectly influence carboxylation of osteocalcin and MGP. Some studies suggest links between VKORC1 variants and bone mineral density or vascular calcification, but the evidence for a direct clinical role in menopause is weak and inconsistent. Most data come from warfarin research or population genetics. For menopause management, general advice on vitamin K-rich foods (kale, broccoli) is more evidence-based than genotyping. Caveat: Direct-to-consumer tests reporting VKORC1 SNPs do not provide validated guidance for menopause. Evidence: mechanistic, insufficient for clinical decisions.